In December 2021, the FDAput a clinical holdon Sunlenca trials due to safety concerns about the glass vials used for the injectable formulation.The hold was liftedin May 2022, after Gilead switched to a different type of glass.During the hold, CAPELLA and CALIBRATE participants were unable to...